CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0513 (clinicaltrials.gov NCT No: NCT00474747)
Title:Fludarabine-based conditioning for allogeneic marrow transplantation from HLA-compatible unrelated donors in severe aplastic anemia
Principal Investigator:Paolo Anderlini
Treatment Agent:Antithymocyte Globulin; Cyclophosphamide; Fludarabine
Study Status:Closed
Study Description:The goal of this clinical research study is to find out the best dose of
cyclophosphamide that can be given with fludarabine, antithymocyte globulin
(ATG), and low-dose total body irradiation (TBI) to patients before a bone
marrow transplant to decrease the risks related to the transplant while not
decreasing the effectiveness of the transplant from an unrelated donor.

Hide details for General InformationGeneral Information

Disease Group:Blood And Marrow Transplantation; Hematologic Disorder
Phase of Study:Phase I/Phase II
Treatment Agents:Antithymocyte Globulin
Cyclophosphamide
Fludarabine
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:4-5 weeks (uncomplicated cases)
Supported By:N/A
Return Visit:2-4 times a week until day 100 after transplant, then every 2-4 months
thereafter as per current BMT guidelines
Home Care:Antibiotics, antifungals, antivirals, intravenous fluids (supportive care)


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Paolo Anderlini
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults